

# **U.S. Next Generation Diabetes Therapy and Drug Delivery Market by Product Type (Inhalable Insulin, Oral Insulin, Insulin Patch, CGM System, and Artificial Pancreas), Demographic (Adult Population and Child Population), Indication (Type I Diabetes and Type II Diabetes), and End User (Diagnostics/Clinic, ICU, and Home Healthcare) - U.S. Opportunity Analysis and Industry Forecast, 2014-2023**

<https://marketpublishers.com/r/U69EF36DC26EN.html>

Date: April 2018

Pages: 124

Price: US\$ 3,255.00 (Single User License)

ID: U69EF36DC26EN

## **Abstracts**

The U.S. next generation diabetes therapy and drug delivery market was valued at \$446 million in 2015, and is estimated to reach \$6,510 million by 2023, registering a CAGR of 33.0% from 2017 to 2023. Next generation diabetes therapy and drug delivery devices are used to accurately check the blood glucose levels and deliver insulin into the body. Next generation diabetes drug delivery systems such as oral and inhalable insulin help to introduce insulin into the patient's body without causing pain and also reduces the risk of skin irritation due to frequent use of needles.

The U.S. next generation diabetes therapy and drug delivery market is segmented based on product type, demographic, end user, and region. The product type segment includes inhalable insulin, oral insulin, insulin patch, continuous glucose monitoring systems (CGMS), and artificial pancreas. Based on demographic, the market is bifurcated into adult population (>14years) and child population (?14years). Based on indication, the market is divided into diabetes I and II. Based on end user, the market is categorized into diagnostics/clinic, ICU, and home healthcare.

Rise in the number of diabetic cases and the benefits of using these advanced devices over conventional products boost the market growth. The well-established healthcare infrastructure and high R&D activities for the advancement in diabetes therapeutic

technology are expected to provide opportunities for market growth. However, less variability in products and cost restraints among low and middle-income population are expected to hinder the market growth. Development of affordable products with fewer side effects and presence of undiagnosed diabetic patients in the U.S. are projected to help to open new doors for the growth of the next generation diabetes therapy and drug delivery market.

#### KEY MARKET BENEFITS

This report offers a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities.

The market estimations provided are based on comprehensive analysis of the key developments in the industry.

The U.S. next generation diabetes therapy and drug delivery market is comprehensively analyzed with respect to product type, demographics, indications, and end user.

The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

#### KEY MARKET SEGMENTS

##### By Product Type

Inhalable Insulin

Oral Insulin

Insulin Patch

CGM System

Artificial Pancreas

##### By Demographic

Adult Population (>14 years)

Child Population (?14 years)

#### By End User

Diagnostics/Clinic

ICU

Home Healthcare

#### KEY PLAYERS PROFILED

Abbott Laboratories

Echo Therapeutics, Inc.

F. Hoffmann-La Roche Ltd.

GlySens Incorporated

Medtronic Plc

Sanofi

Novo Nordisk

MannKind Corporation

Dexcom, Inc.

Senseonics Holding, Inc.

The other players of the catheters market include (companies not profiled in the report):

Synertech

Zosano Pharma Corp.

Relmada Therapeutics, Inc.

Eli Lilly and Company

Enteris BioPharma

Transdermal Specialties Inc.

## Contents

### **CHAPTER 1 INTRODUCTION**

- 1.1. REPORT DESCRIPTION
- 1.2. KEY BENEFITS
- 1.3. KEY MARKET SEGMENTS
- 1.4. RESEARCH METHODOLOGY
  - 1.4.1. Secondary research
  - 1.4.2. Primary research
  - 1.4.3. Analyst tools and models

### **CHAPTER 2 EXECUTIVE SUMMARY**

- 2.1. CXO PERSPECTIVE

### **CHAPTER 3 MARKET OVERVIEW**

- 3.1. KEY BENEFITS
  - 3.1.1. Top investment pockets
  - 3.1.2. Top winning strategies
- 3.2. PATENT ANALYSIS
  - 3.2.1. Patent analysis by year
  - 3.2.2. Patent analysis by product
- 3.3. GOVERNMENT REGULATIONS
  - 3.3.1. U.S. FDA
- 3.4. REIMBURSEMENT POLICIES
- 3.5. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET
  - 3.5.1. Smart contact lenses for glucose monitoring
  - 3.5.2. iLet bihormonal bionic pancreas
  - 3.5.3. Glucose nanosensors
  - 3.5.4. Beta cell replacement therapy
  - 3.5.5. Glucose-responsive insulin-producing cells
- 3.6. MARKET DYNAMICS
  - 3.6.1. Drivers
    - 3.6.1.1. Rise in incidence of diabetes
    - 3.6.1.2. Rise in healthcare expenditure & disposable income
    - 3.6.1.3. Benefits of using next generation diabetes products over conventional

products

### 3.6.2. Restraints

3.6.2.1. Cost restrains

3.6.2.2. Lack of awareness

3.6.2.3. Less variability in products

### 3.6.3. Opportunities

3.6.3.1. Developing products with fewer side effects at affordable costs

3.6.3.2. High undiagnosed diabetic patient population

## **CHAPTER 4 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT**

### 4.1. OVERVIEW

4.1.1. Market size and forecast

### 4.2. INHALABLE INSULIN

4.2.1. Key market trends

4.2.2. Key growth factors and opportunities

4.2.3. Market size and forecast

### 4.3. ORAL INSULIN

4.3.1. Key market trends

4.3.2. Key growth factors and opportunities

4.3.3. Market size and forecast

### 4.4. INSULIN PATCHES

4.4.1. Key market trends

4.4.2. Key growth factors and opportunities

4.4.3. Market size and forecast

### 4.5. CGMS

4.5.1. Key market trends

4.5.2. Key growth factors and opportunities

4.5.3. Market size and forecast

### 4.6. ARTIFICIAL PANCREAS

4.6.1. Key market trends

4.6.2. Key growth factors and opportunities

4.6.3. Market size and forecast

## **CHAPTER 5 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS**

### 5.1. OVERVIEW

- 5.1.1. Market size and forecast
- 5.2. ADULT POPULATION (>14YEARS)
  - 5.2.1. Market size and forecast
- 5.3. CHILD POPULATION (14YEARS)
  - 5.3.1. Market size and forecast

## **CHAPTER 6 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION**

- 6.1. OVERVIEW
  - 6.1.1. Market size and forecast
- 6.2. TYPE I DIABETES
  - 6.2.1. Market size and forecast
- 6.3. TYPE II DIABETES
  - 6.3.1. Market size and forecast

## **CHAPTER 7 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER**

- 7.1. OVERVIEW
  - 7.1.1. Market size and forecast
- 7.2. DIAGNOSTICS/CLINICS
  - 7.2.1. Market size and forecast
- 7.3. INTENSIVE CARE UNITS (ICU)
  - 7.3.1. Market size and forecast
- 7.4. HOME HEALTHCARE
  - 7.4.1. Market size and forecast

## **CHAPTER 8 COMPANY PROFILES**

- 8.1. ABBOTT LABORATORIES
  - 8.1.1. Company overview
  - 8.1.2. Company snapshot
  - 8.1.3. Operating business segments
  - 8.1.4. Product portfolio
  - 8.1.5. Business performance
  - 8.1.6. Key strategic moves and developments
- 8.2. DEXCOM, INC.
  - 8.2.1. Company overview

- 8.2.2. Company snapshot
- 8.2.3. Product portfolio
- 8.2.4. Business performance
- 8.2.5. Key strategic moves and developments
- 8.3. ECHO THERAPEUTICS, INC.
  - 8.3.1. Company overview
  - 8.3.2. Company snapshot
  - 8.3.3. Operating business segments
  - 8.3.4. Product portfolio
- 8.4. F. HOFFMANN-LA ROCHE LTD.
  - 8.4.1. Company overview
  - 8.4.2. Company snapshot
  - 8.4.3. Operating business segments
  - 8.4.4. Product portfolio
  - 8.4.5. Business performance
  - 8.4.6. Key strategic moves and developments
- 8.5. GLYSENS INCORPORATED
  - 8.5.1. Company overview
  - 8.5.2. Company snapshot
  - 8.5.3. Product portfolio
  - 8.5.4. Key strategic moves and developments
- 8.6. MANKIND CORPORATION
  - 8.6.1. Company overview
  - 8.6.2. Company snapshot
  - 8.6.3. Operating business segments
  - 8.6.4. Product portfolio
  - 8.6.5. Business performance
- 8.7. MEDTRONIC PLC.
  - 8.7.1. Company overview
  - 8.7.2. Company snapshot
  - 8.7.3. Operating business segments
  - 8.7.4. Product portfolio
  - 8.7.5. Business performance
  - 8.7.6. Key strategic moves and developments
- 8.8. NOVO NORDISK A/S
  - 8.8.1. Company overview
  - 8.8.2. Company snapshot
  - 8.8.3. Operating business segments
  - 8.8.4. Product portfolio



8.8.5. Business performance

8.9. SANOFI

8.9.1. Company overview

8.9.2. Company snapshot

8.9.3. Operating business segments

8.9.4. Product portfolio

8.9.5. Business performance

8.9.6. Key strategic moves and developments

8.10. SENSEONICS HOLDINGS, INC.

8.10.1. Company overview

8.10.2. Company snapshot

8.10.3. Operating business segments

8.10.4. Product portfolio

8.10.5. Business performance

8.10.6. Key strategic moves and developments

## List Of Tables

### LIST OF TABLES

TABLE 1. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2014-2023 (\$THOUSAND)

TABLE 2. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 (\$THOUSAND)

TABLE 3. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2014-2023 (\$THOUSAND)

TABLE 4. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2014-2023 (\$THOUSAND)

TABLE 5. ABBOTT: COMPANY SNAPSHOT

TABLE 6. ABBOTT: OPERATING SEGMENTS

TABLE 7. ABBOTT: PRODUCT PORTFOLIO

TABLE 8. DEXCOM: COMPANY SNAPSHOT

TABLE 9. DEXCOM: PRODUCT PORTFOLIO

TABLE 10. ECHO THERAPEUTICS: COMPANY SNAPSHOT

TABLE 11. ECHO THERAPEUTICS: OPERATING SEGMENTS

TABLE 12. ECHO THERAPEUTICS: PRODUCT PORTFOLIO

TABLE 13. ROCHE: COMPANY SNAPSHOT

TABLE 14. ROCHE: OPERATING SEGMENTS

TABLE 15. ROCHE: PRODUCT PORTFOLIO

TABLE 16. GLYSENS: COMPANY SNAPSHOT

TABLE 17. GLYSENS: PRODUCT PORTFOLIO

TABLE 18. MANNKIND: COMPANY SNAPSHOT

TABLE 19. MANNKIND: PRODUCT PORTFOLIO

TABLE 20. MEDTRONIC: COMPANY SNAPSHOT

TABLE 21. MEDTRONIC: OPERATING SEGMENTS

TABLE 22. MEDTRONIC: PRODUCT PORTFOLIO

TABLE 23. NOVO NORDISK: COMPANY SNAPSHOT

TABLE 24. NOVO NORDISK: OPERATING SEGMENTS

TABLE 25. NOVO NORDISK: PRODUCT PORTFOLIO

TABLE 26. SANOFI: COMPANY SNAPSHOT

TABLE 27. SANOFI: OPERATING SEGMENTS

TABLE 28. SANOFI: PRODUCT PORTFOLIO

TABLE 29. SENSEONICS: COMPANY SNAPSHOT

TABLE 30. SENSEONICS: PRODUCT SEGMENTS

TABLE 31. SENSEONICS: PRODUCT PORTFOLIO



## List Of Figures

### LIST OF FIGURES

FIGURE 1. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET: SEGMENTATION

FIGURE 2. TOP INVESTMENT POCKETS, BY PRODUCT

FIGURE 3. TOP WINNING STRATEGIES, BY YEAR, 2015-2018

FIGURE 4. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018 (%)

FIGURE 5. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018

FIGURE 6. PATENT REGISTERED/APPROVED, BY YEAR

FIGURE 7. PATENT REGISTERED/APPROVED, BY PRODUCT

FIGURE 8. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR INHALABLE INSULIN, 2014-2023 (\$THOUSAND)

FIGURE 9. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ORAL INSULIN, 2014-2023 (\$THOUSAND)

FIGURE 10. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR INSULIN PATCH, 2014-2023 (\$THOUSAND)

FIGURE 11. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR CGM SYSTEMS, 2014-2023 (\$THOUSAND)

FIGURE 12. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ARTIFICIAL PANCREAS, 2014-2023 (\$THOUSAND)

FIGURE 13. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ADULT POPULATION, 2014-2023 (\$THOUSAND)

FIGURE 14. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR CHILD POPULATION, 2014-2023 (\$THOUSAND)

FIGURE 15. NEXT GENERATION TYPE I DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 (\$THOUSAND)

FIGURE 16. NEXT GENERATION TYPE II DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 (\$THOUSAND)

FIGURE 17. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR DIAGNOSTICS/CLINICS, 2014-2023 (\$THOUSAND)

FIGURE 18. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ICUS, 2014-2023 (\$THOUSAND)

FIGURE 19. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR HOME HEALTHCARE, 2014-2023 (\$THOUSAND)

FIGURE 20. ABBOTT: NET SALES, 2015-2017 (\$MILLION)

FIGURE 21. ABBOTT: REVENUE SHARE BY SEGMENT, 2017 (%)

FIGURE 22. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

- FIGURE 23. DEXCOM: NET SALES, 2015-2017 (\$MILLION)
- FIGURE 24. DEXCOM: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
- FIGURE 25. ROCHE: NET SALES, 2015-2017 (\$MILLION)
- FIGURE 26. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
- FIGURE 27. MANNKIND: NET SALES, 2016-2017 (\$MILLION)
- FIGURE 28. MEDTRONIC: NET SALES, 2015-2017 (\$MILLION)
- FIGURE 29. MEDTRONIC: REVENUE SHARE BY SEGMENT, 2017 (%)
- FIGURE 30. MEDTRONIC: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
- FIGURE 31. NOVO NORDISK: NET SALES, 2015-2017 (\$MILLION)
- FIGURE 32. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2017 (%)
- FIGURE 33. NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
- FIGURE 34. SANOFI: NET SALES, 2015-2017 (\$MILLION)
- FIGURE 35. SANOFI: REVENUE SHARE BY SEGMENT, 2017 (%)
- FIGURE 36. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
- FIGURE 37. SENSEONICS: NET SALES, 2015-2017 (\$MILLION)

## I would like to order

Product name: U.S. Next Generation Diabetes Therapy and Drug Delivery Market by Product Type (Inhalable Insulin, Oral Insulin, Insulin Patch, CGM System, and Artificial Pancreas), Demographic (Adult Population and Child Population), Indication (Type I Diabetes and Type II Diabetes), and End User (Diagnostics/Clinic, ICU, and Home Healthcare) - U.S. Opportunity Analysis and Industry Forecast, 2014-2023

Product link: <https://marketpublishers.com/r/U69EF36DC26EN.html>

Price: US\$ 3,255.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U69EF36DC26EN.html>